MYND Life Sciences (TSE:MYND) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MYND Life Sciences plans to issue 4 million shares to eliminate $3.5 million in debt, including restructuring an outstanding debenture, to enhance shareholder value and focus on developing their biomarker test for depression. This strategic financial move aims to strengthen MYND’s position and accelerate the development of a potentially groundbreaking diagnostic tool for major depressive disorder.
For further insights into TSE:MYND stock, check out TipRanks’ Stock Analysis page.